Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-18
2008-10-07
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S184000
Reexamination Certificate
active
07432283
ABSTRACT:
This invention relates to a method for modulating α2subtype GABAAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain
REFERENCES:
patent: 5668145 (1997-09-01), Bright
patent: 5705646 (1998-01-01), Bright et al.
patent: 5712303 (1998-01-01), Faraci et al.
patent: 5760225 (1998-06-01), Yuan
patent: 6200979 (2001-03-01), Bright et al.
patent: 6821984 (2004-11-01), Loughhead et al.
patent: 7053103 (2006-05-01), Loughhead et al.
patent: 2003/0187014 (2003-10-01), Uehikawa et al.
patent: WO 01/44244 (2001-06-01), None
patent: WO 03/048160 (2003-06-01), None
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, 975.
Banker, Gilbert S. et al., Modem Pharmaceutics, Marcel Dekker, New York, 1996.
Hehemann, et al., “Addition of Diamines to Methylthiopyridones,”J. Heterocyclic Chem., (1994), pp. 393-396, vol. 31 (2).
Mohareb, et al., “Reactions with 4-Phenyl-3-thiosemicarbazide: A New Approach for the Synthesis of Pyrazole, Thiazole, Pyridine and Pyrazolo[3,4-b]-Pyridine Derivatives,”Sulfur Letters, (1991), pp. 101-113, vol. 13(3).
Thompson, et al. “Tracazolate Reveals a Novel Ty[e of Allosteric Interactioin with Recombinanty-Aminobutyric AcidAeceptors,” (Apr. 2002), pp. 861-869, vol. 61:4.
Cooke, et al., “α-Subunit selective modulators of GABAAreceptor function as CNS therapeutics,” (Oct. 2002), pp. 1491-1501, vol. 12:10.
Loughhead David Garrett
Novakovic Sanja
O'Yang Counde
Putman David George
Soth Michael
Buckwalter Brian L.
Leeser Erich A
Roche Palo Alto LLC
Wilson James O.
LandOfFree
Heterocyclic GABA A subtype selective receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic GABA A subtype selective receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic GABA A subtype selective receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4014155